Rheumatoid ArthritisPhase 4NCT01313208
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
A Phase 4 study testing etanercept and DMARD Therapy in people with Rheumatoid Arthritis, run by Amgen at 47 sites in 2 countries.
Trial summary
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- etanercept and DMARD Therapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 210 participants
- Where
- 47 sitesin 2 countries
- Study dates
- Mar 2011to May 2013
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female ≥18 and ≤80 years of age at time of screening
- Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College of Rheumatology (ACR) classification criteria and has had rheumatoid arthritis for at least 6 months
- Moderate rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2 and ≤ 5.1
- Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined) and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline. (A full 66/68 count joint count will be performed at baseline, but only joints in the 28-count joint count will be considered for eligibility. The 28-joint count consists of the finger joints excluding the distal interphalangeal joints, the wrists, elbows, shoulders, and knees)
- Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Who cannot join
- Prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening
- Class IV rheumatoid arthritis according to ACR revised response criteria
- Any active infection (including chronic or localized infections) for which anti-infectives were indicated within 28 days prior to first investigational product dose
- Previously used more than one experimental biologic DMARD. Patient with prior use of no more than one experimental biologic is permitted if the subject received no more than 8 weeks of treatment. The use of the experimental biologic must not have occurred within 2 months of the first dose of investigational product
- Previously used more than one commercially available biologic DMARD. Subject with prior use of no more than one commercially available biologic is permitted if the patient received no more than 8 weeks of treatment and did not discontinue because of lack of effect. The use of the biologic must not have occurred within 2 months of the first dose of investigational product. Acceptable prior use of biologics include the following examples:
- No more than 4 injections of adalimumab
Show all 10Show fewer
- No more than 8 (50 mg) injections of etanercept
- No more than 2 infusions of infliximab
- No more than 2 infusions of abatacept
- Additional inclusion (exclusion) criteria may apply
Trial locations and contacts
47 sites in 2 countries.
47 sites in 2 countries
United States38 sites
Research Site
Akron, Ohio, 44311
Research Site
Atlanta, Georgia, 30342
Research Site
Birmingham, Alabama, 35205
Research Site
Bismarck, North Dakota, 58501
Research Site
Chesapeake, Virginia, 23320
Research Site
Dallas, Texas, 75231
Research Site
Denver, Colorado, 80230
Research Site
Encino, California, 91436
Research Site
Erie, Pennsylvania, 16508
Research Site
Frederick, Maryland, 21702
Research Site
Greer, South Carolina, 29650
Research Site
Hemet, California, 92543
Research Site
Inglewood, California, 90301
Research Site
Jacksonville, Florida, 32209
Research Site
La Jolla, California, 92037
Research Site
Lansing, Michigan, 48910
Research Site
Lexington, Kentucky, 40504
Research Site
Mayfield Village, Ohio, 44143
Research Site
Meridian, Idaho, 83642
Research Site
Murrieta, California, 92563
Research Site
Ocala, Florida, 34474
Research Site
Oklahoma City, Oklahoma, 73103
Research Site
Oklahoma City, Oklahoma, 73109
Research Site
Peoria, Arizona, 85381
Research Site
Portland, Oregon, 97239
Research Site
Saint Clair Shores, Michigan, 48081
Research Site
San Antonio, Texas, 78232
Research Site
Santa Maria, California, 93454
Research Site
Sarasota, Florida, 34239
Research Site
Scottsdale, Arizona, 85258
Research Site
Seattle, Washington, 98133
Research Site
Sebring, Florida, 33870
Research Site
Springfield, Illinois, 62704
Research Site
Tampa, Florida, 33613
Research Site
Tuscaloosa, Alabama, 35406
Research Site
Tustin, California, 92780
Research Site
Upland, California, 91786
Research Site
Victorville, California, 92395
Canada9 sites
Research Site
Burlington, Ontario, L7R 1E2
Research Site
Laval, Quebec, H7T 2P5
Research Site
Montreal, Quebec, H1T 2M4
Research Site
Montreal, Quebec, H2L 1S6
Research Site
Montreal, Quebec, H3Z 2Z3
Research Site
Québec, Quebec, G1V 3M7
Research Site
Saint-Eustache, Quebec, J7P 4J2
Research Site
St. John's, Newfoundland and Labrador, A1C 5B8
Research Site
Winnipeg, Manitoba, R3A 1M3
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
- Conditions
- Rheumatoid Arthritis
- Being tested
- etanercept, Placebo, DMARD Therapy
- Keywords
- RA, Enbrel, DMARD, Joint Count, Rheumatoid Arthritis, Etanercept, disease modifying anti-rheumatic drug
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
etanerceptDrug
Also called Enbrel
Administered by subcutaneous injection once weekly.
PlaceboDrug
Placebo subcutaneous injection
DMARD TherapyDrug
Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.
All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period. Receives: Drug: etanercept; Drug: Placebo; Drug: DMARD Therapy |
| Etanercept | Experimental | Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.
All participants continued their DMARD treatment throughout the 24-week study period. Receives: Drug: etanercept; Drug: DMARD Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12
Low disease activity is defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) of less than 3.2. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: • The number of swollen and tender joints assessed using the 28-joint count; • C-Reactive Protein (CRP) level • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).
The DAS28 score ranges from zero up to approximately ten. DAS28 scores above 5.1 indicate high disease activity.
Measured: Week 12
Secondary outcomes (41)
Percentage of Participants Achieving DAS28 Remission at Week 12
Remission is defined by a DAS28 score less than 2.6. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:
- The number of swollen and tender joints assessed using the 28-joint count;
- C-reactive protein (CRP)
- Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).
The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity.
Measured: Week 12
Percentage of Participants Achieving DAS28 Low Disease Activity at All Other Timepoints
Low disease activity is defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) of less than 3.2. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:
- The number of swollen and tender joints assessed using the 28-joint count;
- C-Reactive Protein (CRP) level
- Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).
The DAS28 score ranges from zero up to approximately ten. DAS28 scores above 5.1 indicate high disease activity.
Measured: Baseline and Weeks 2, 4, 8, 16, 20 and 24
Percentage of Participants Achieving DAS28 Remission at All Other Timepoints
Remission is defined by a DAS28 score less than 2.6. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:
- The number of swollen and tender joints assessed using the 28-joint count;
- C-reactive protein (CRP)
- Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).
The DAS28 score ranges from zero to ten. A DAS28 above 5.1 indicates high disease activity.
Measured: Baseline and Weeks 2, 4, 8, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Each Timepoint
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); ◦ Patient's global assessment of disease activity (measured on a likert scale from 0 to 10); ◦ Physician's global assessment of disease activity (measured on a likert scale from 0 to 10); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); ◦ C-Reactive Protein level.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Each Timepoint
A participant was a responder if the following 3 criteria for improvement from Baseline were met:
- ≥ 50% improvement in tender joint count;
- ≥ 50% improvement in swollen joint count; and
- ≥ 50% improvement in at least 3 of the 5 following parameters:
- Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
- Patient's global assessment of disease activity (measured on a likert scale from 0 to 10);
- Physician's global assessment of disease activity (measured on a likert scale from 0 to 10);
- Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
- C-reactive protein (CRP) level.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Each Timepoint
A participant was a responder if the following 3 criteria for improvement from Baseline were met:
- ≥ 70% improvement in tender joint count;
- ≥ 70% improvement in swollen joint count; and
- ≥ 70% improvement in at least 3 of the 5 following parameters:
- Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
- Patient's global assessment of disease activity (measured on a likert scale from 0 to 10);
- Physician's global assessment of disease activity (measured on a likert scale from 0 to 10);
- Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
- C-reactive protein (CRP) level.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With RAPID3 Remission or Low Severity at Each Time Point
The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) is adapted from the standard HAQ and is used for the computation of the Routine Assessment of Patient Index Data 3 (RAPID3). The RAPID 3 includes the 3 Core Data Set measures of physical function, pain, and patient global estimate. The score for physical function ranges from 0 to 10 and is calculated by adding the ten activities of daily living, each scored from 0 to 3 by the patient (0="without any difficulty", 1="with some difficulty", 2="with much difficulty", and 3="unable to do") and dividing the total raw score by 3. Pain and global estimate of health are measured on a likert scale from 0 to 10, both scored 0 (best) to 10 (worst). The three 0-10 scores for physical function, pain, and global assesment of health are added together for a composite score of 0 to 30. The RAPID3 composite score includes 4 categories: High Severity > 12, Moderate Severity = 6.1 - 12, Low severity = 3.1 - 6, and Remission ≤ 3.
Measured: Baseline and Weeks 4, 12, and 24
Percentage of Participants Achieving Count Remission at Each Time Point
Count remission is achieved when a participant satisfies all of the following at any given time point: - 68 tender joint count ≤ 1, - 66 swollen joint count ≤ 1, - C-reactive protein (CRP) (in mg/dL) ≤1, and - patient global assessment of disease activity ≤ 1 (measured on a likert scale from 0 to 10 ranging from "no activity at all" to "worst activity imaginable").
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving CDAI Remission at Each Time Point
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:
- 28 tender joint count (TJC),
- 28 swollen joint count (SJC),
- Patient's Global Assessment of Disease Activity measured on a likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest;
- Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest.
The CDAI score ranges from 0-76 where lower scores indicate less disease activity. CDAI remission is defined as a score ≤ 2.8.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving CDAI Low Disease Activity at Each Time Point
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:
- 28 tender joint count (TJC),
- 28 swollen joint count (SJC),
- Patient's Global Assessment of Disease Activity measured on a Likert scale form 0 to 10, where 0 = lowest disease activity and 10 = highest;
- Physician's Global Assessment of Disease Activity -measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest. The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity. CDAI low disease activity is defined as a score ≤ 10.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Clinical Disease Activity Index (CDAI) Score at Each Time Point
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:
- 28 tender joint count (TJC),
- 28 swollen joint count (SJC),
- Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest;
- Physician's Global Assessment of Disease Activity (measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest).
The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving SDAI Remission at Each Time Point
The simplified disease activity index (SDAI) is a composite measure that sums the total number of:
- 28 tender joint counts,
- 28 swollen joint counts,
- Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0= lowest disease activity and 10 = highest;
- Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest, and
- C-reactive protein (CRP) in mg/dL.
The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity. SDAI remission is defined as a score ≤ 3.3.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving SDAI Low Disease Activity at Each Time Point
The simplified disease activity index (SDAI) is a composite measure that sums the total number of: - 28 tender joint counts, - 28 swollen joint counts, - Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest; - Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest, and - C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity. SDAI low disease activity is defined as a score ≤ 11.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Simplified Clinical Disease Activity Index (SDAI) Score at Each Time Point
The simplified disease activity index (SDAI) is a composite measure that sums the total number of:
- 28 tender joint counts,
- 28 swollen joint counts,
- Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest;
- Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest, and
- C-reactive protein (CRP) in mg/dL.
The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Tender 28-Joint Count (TJC28) at Each Time Point
Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Swollen 28-Joint Count (SJC28) at Each Time Point
Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Patient Global Assessment of Joint Pain at Each Time Point
The severity of the participant's joint pain was assessed using a visual analog scale (VAS). The participant was asked to draw a mark through a 100 mm horizontal line to indicate how much pain they were experiencing "today", from '0' (no pain at all) on the left end of the line to 100 (worst pain imaginable) on the right end of the line.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Patient's Global Assessment of Disease Activity at Each Time Point
The participant's global assessment of their arthritis disease activity was assessed by the participant circling a number from 0 to 10 on a horizontal Likert scale ranging from "No Activity at All" (score = 0) to "Worst Activity Imaginable" (score = 10).
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Physician Global Assessment of Disease Activity at Each Time Point
The global assessment of the participant's arthritis was assessed by the physician circling a number from 0 to 10 on a horizontal Likert scale ranging from "No Activity at All" (score = 0) to "Worst Activity Imaginable" (score = 10).
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Each Time Point
The HAQ-DI asks about the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores). Responses in each functional area are scored from 0 indicating no difficulty to 3 indicating inability to perform a task in that area. The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
C-reactive Protein Levels at Each Time Point
C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The physical functioning subscale assesses limitations in physical activities because of health problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Vitality Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The vitality sub-score assesses energy and fatigue. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Role-Physical Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The role-physical subscale assesses limitations in usual role activities because of physical health problems. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning (less pain). Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) General Health Perceptions Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Social Functioning Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Role-Emotional Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Mental Health Domain Score at Each Time Point
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. The mental health sub-score assesses general mental health (psychological distress and well-being). Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Work Time Missed (Absenteeism) at Each Time Point
This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to rheumatoid arthritis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Impairment While Working (Presenteeism) at Each Time Point
This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which rheumatoid arthritis affected their productivity while working. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Activity Impairment at Each Time Point
This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis. Percent activity impairment is derived from the patient's assessment of the degree to which rheumatoid arthritis affected their regular daily activities. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Overall Work Impairment at Each Time Point
This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent overall work impairment takes into account both hours missed due to rheumatoid arthritis symptoms and the participant's assessment of the degree to which rheumatoid arthritis affected their productivity while working. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Participant Assessment of Fatigue at Each Time Point
The participant's assessment of fatigue was collected using a single-item 100 mm visual analogue scale. The participant was asked to draw a vertical line through a horizontal line to indicate the degree of fatigue they experienced because of their condition over the past week. The horizontal line is 100 mm in length with '0' and 'no fatigue' on the left end of the line and '100' and 'extreme fatigue' on the right end of the line. Least squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Medical Outcomes Study (MOS) Sleep Disturbance Scale at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Shortness of Breath (1 item). Sleep Disturbance measures the ability to fall asleep and to maintain restful sleep. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Shortness of Breath or Headache Scale at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Snoring Scale at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Shortness of Breath (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Adequacy Scale at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). Sleep Adequacy measures sleep sufficiency in terms of whether the participant sleeps enough to provide restoration of wakefulness. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. For sleep adequacy a higher score indicates better sleep quality. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Daytime Somnolence Scale at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). Daytime somnolence measures drowsiness or sleepiness during the day. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Problems Index I at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). The scale also produces two indices. The Sleep Problems Index-I is drawn from 6 items in the four domains including Sleep Disturbance (2 items), Sleep Adequacy (2 items), Shortness of Breath (1 item), and Daytime Somnolence (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Problems Index II at Each Time Point
The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). The scale also produces two indices. Index-II uses 9 items from four domains including Sleep Disturbance (4 items), Sleep Adequacy (2 items), Shortness of Breath (1 item), and Daytime Somnolence (2 items). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).
Measured: Baseline and Weeks 4, 12 and 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2011 (estimated)
- Study startMar 2011
- Primary completionFeb 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 210 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01313208
- Sponsor's protocol ID
- 20070561
- Status last verified
- Feb 2017
- First submitted
- 10 Mar 2011
- Last updated
- 9 Feb 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, Collier DH. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus. 2015 Mar 5;4:113. doi: 10.1186/s40064-015-0895-9. eCollection 2015.
PubMed 25793152
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
- ClinicalTrials.gov ID
- NCT01313208
- Acronym / sponsor ID
- 20070561
- Conditions
- Rheumatoid Arthritis
- Keywords
- RA, Enbrel, DMARD, Joint Count, Rheumatoid Arthritis, Etanercept, disease modifying anti-rheumatic drug
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 210 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- Mar 2011
- Primary completion
- Feb 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 11 Mar 2011 (estimated)
- Results
- Posted 17 Jun 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: etanercept, Drug: Placebo, Drug: DMARD TherapyParticipants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks. All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period. |
| Etanercept | Experimental | Drug: etanercept, Drug: DMARD TherapyParticipants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks. All participants continued their DMARD treatment throughout the 24-week study period. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female ≥18 and ≤80 years of age at time of screening
- Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College of Rheumatology (ACR) classification criteria and has had rheumatoid arthritis for at least 6 months
- Moderate rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2 and ≤ 5.1
- Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined) and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline. (A full 66/68 count joint count will be performed at baseline, but only joints in the 28-count joint count will be considered for eligibility. The 28-joint count consists of the finger joints excluding the distal interphalangeal joints, the wrists, elbows, shoulders, and knees)
- Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Key exclusion criteria (10 listed)
- Prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening
- Class IV rheumatoid arthritis according to ACR revised response criteria
- Any active infection (including chronic or localized infections) for which anti-infectives were indicated within 28 days prior to first investigational product dose
- Previously used more than one experimental biologic DMARD. Patient with prior use of no more than one experimental biologic is permitted if the subject received no more than 8 weeks of treatment. The use of the experimental biologic must not have occurred within 2 months of the first dose of investigational product
- Previously used more than one commercially available biologic DMARD. Subject with prior use of no more than one commercially available biologic is permitted if the patient received no more than 8 weeks of treatment and did not discontinue because of lack of effect. The use of the biologic must not have occurred within 2 months of the first dose of investigational product. Acceptable prior use of biologics include the following examples:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| etanerceptAlso: EnbrelAdministered by subcutaneous injection once weekly. | Drug | Etanercept, Placebo |
| PlaceboPlacebo subcutaneous injection | Drug | Placebo |
| DMARD TherapyStandard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine | Drug | Etanercept, Placebo |
Primary outcome
Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12
Time frame: Week 12
Low disease activity is defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) of less than 3.2. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: • The number of swollen and tender joints assessed using the 28-joint count; • C-Reactive Protein (CRP) level • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity). The DAS28 score ranges from zero up to approximately ten. DAS28 scores above 5.1 indicate high disease activity.
41 secondary outcomes
Percentage of Participants Achieving DAS28 Remission at Week 12
Time frame: Week 12
Percentage of Participants Achieving DAS28 Low Disease Activity at All Other Timepoints
Time frame: Baseline and Weeks 2, 4, 8, 16, 20 and 24
Percentage of Participants Achieving DAS28 Remission at All Other Timepoints
Time frame: Baseline and Weeks 2, 4, 8, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Each Timepoint
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Each Timepoint
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Each Timepoint
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With RAPID3 Remission or Low Severity at Each Time Point
Time frame: Baseline and Weeks 4, 12, and 24
Percentage of Participants Achieving Count Remission at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving CDAI Remission at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving CDAI Low Disease Activity at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Clinical Disease Activity Index (CDAI) Score at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving SDAI Remission at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving SDAI Low Disease Activity at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Simplified Clinical Disease Activity Index (SDAI) Score at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Tender 28-Joint Count (TJC28) at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Swollen 28-Joint Count (SJC28) at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Patient Global Assessment of Joint Pain at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Patient's Global Assessment of Disease Activity at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Physician Global Assessment of Disease Activity at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
C-reactive Protein Levels at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Vitality Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Role-Physical Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) General Health Perceptions Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Social Functioning Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Role-Emotional Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Short Form 36 Health Survey (SF-36) Mental Health Domain Score at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Work Time Missed (Absenteeism) at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Impairment While Working (Presenteeism) at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Activity Impairment at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Overall Work Impairment at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Participant Assessment of Fatigue at Each Time Point
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Medical Outcomes Study (MOS) Sleep Disturbance Scale at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Shortness of Breath or Headache Scale at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Snoring Scale at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Adequacy Scale at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Daytime Somnolence Scale at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Medical Outcomes Study (MOS) Sleep Problems Index I at Each Time Point
Time frame: Baseline and Weeks 4, 12 and 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 25793152Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, Collier DH. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus. 2015 Mar 5;4:113. doi: 10.1186/s40064-015-0895-9. eCollection 2015.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
47 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing etanercept and DMARD Therapy in people with Rheumatoid Arthritis, run by Amgen at 47 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 47 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Jun 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01313208, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2017.